SB1467 HFLR Page 1
BOLD FACE denotes Committee Amendm ents. 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
HOUSE OF REPRESENTATIVES - FLOOR VERSION
STATE OF OKLAHOMA
2nd Session of the 58th Legislature (2022)
ENGROSSED SENATE
BILL NO. 1467 By: David of the Senate
and
Caldwell (Chad) of the
House
An Act relating to the state Medicaid program;
requiring Oklahoma Health Care Authority to conduct
certain annual review; stating purpose ; requiring
review to include certain crit eria; directing
Authority to seek pu blic input; requiring utiliz ation
of Oklahoma State Health Information Network and
Exchange to extent practicable; directing sub mission
and publication of annual report; providin g for
codification; and providing an effective date .
BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA:
SECTION 1. NEW LAW A new section of law to be codified
in the Oklahoma Statutes as Section 5026.1 of Title 63, unless there
is created a duplication in numbering, reads as fo llows:
A. The Oklahoma Health Care Authority shall conduct an annual
review of all medications and forms of treatment for sickle cell
disease and services for enrollees with a diagnosis of sickle cell
disease. The purpose of the annual review is to deter mine if the
available covered medications, treatments, and services are adequate
to meet the needs of enrol lees with a diagnosis of sickle cell
SB1467 HFLR Page 2
BOLD FACE denotes Committee Amendm ents. 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
disease, and whether the Authority should seek to add or recomme nd
additional medications, treatments, or servic es.
B. The review shall include, but not be limited t o:
1. The extent to which healthcare transitional pr ograms covered
under the state Medica id program prepare, transfer, and integrate
emerging adults into the adult care setting from a pediatric
setting;
2. The extent to which emergency department providers are
adequately trained and otherwise prepared to t reat and manage sickle
cell patients presenting with vaso -occlusive crises including but
not limited to the extent to which providers follow clinical ly
validated algorithms an d protocols regarding such t reatment and
management;
3. The extent to which sick le cell patients covered under the
state Medicaid program are entitled to receive the same standard o f
care when referred or transferred to an out -of-state facility, and
the extent to which the state reimburses such patients for
reasonable interstate trave l costs; and
4. Any additional areas identified by the Authority that imp act
the care and treatment of individuals in this state living with
sickle cell disease or sickle cell trait.
C. When conducting the annual review required by this sectio n,
the Authority shall solicit and consider inpu t from the general
public, with specific emphasis on seeking input from persons or
SB1467 HFLR Page 3
BOLD FACE denotes Committee Amendm ents. 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
groups with knowledge and exp erience in the area of sickle cell
disease treatment.
D. To the extent practicable, the Authority shall ut ilize the
Oklahoma State Health Infor mation Network and Excha nge created under
Section 1-133 of Title 63 of the Oklahoma Statutes to collect
information for the purpose of implementing this section.
E. On or before January 15, 2023, and on or before Janua ry 15
each year thereafter, the Autho rity shall submit a report to the
President Pro Tempore of the Senate and the Speaker of the House of
Representatives for distribution to the appropriate subject matter
committees that details the Authority’s findings from the annual
review required by thi s section and any recommendations to the
Legislature based upon those findings. The Authority shall publish
the annual report required by this subsection to its website in a
manner accessible by the general public.
SECTION 2. This act shall become effective November 1, 2022.
COMMITTEE REPORT BY: COMMITTEE ON PUBLIC HEALTH, dated 04/06/2022 -
DO PASS.